LIGAND PHARMACEUTICALS INCORPORATED Payment for Contingent Consideration Liability, Investing Activities
LIGAND PHARMACEUTICALS INCORPORATED (LGNXZ) reported Payment for Contingent Consideration Liability, Investing Activities of $1.00 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-08.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities · last filed 2018-11-08
- LIGAND PHARMACEUTICALS INCORPORATED payment for contingent consideration liability, investing activities for the quarter ending 2018-09-30 was $0.00.
- LIGAND PHARMACEUTICALS INCORPORATED payment for contingent consideration liability, investing activities for the quarter ending 2017-09-30 was $0.00.
| Period end | Payment for Contingent Consideration Liability, Investing Activities 3 month | Payment for Contingent Consideration Liability, Investing Activities 6 month | Payment for Contingent Consideration Liability, Investing Activities 9 month |
|---|---|---|---|
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $1.00M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $1.00M 10-Q · filed 2018-08-08 | ||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $0.00 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $0.00 10-Q · filed 2018-08-08 |